Lam Research's $25B Buyback Fails to Address Core Risks

What happened

Lam Research announced a $25 billion share repurchase authorization and a quarterly dividend of $0.33 per share, signaling aggressive capital return. This follows a pattern of significant buybacks, with $1.16 billion repurchased in the March 2026 quarter and $3.60 billion over nine months, further reducing share count. The company's stock trades at a rich valuation (P/E ~81) with significant China revenue exposure (34-37%), which remains a key risk per the latest deep value report. The buyback authorization, while large, does not alter the fundamental concerns about export controls and potential China demand reset. The market may interpret the buyback as a vote of confidence, but the core thesis remains a WAIT pending clearer evidence on China stability and valuation normalization.

Implication

The $25 billion buyback authorization is a strong signal of management's belief in undervaluation and future cash generation, potentially putting a floor under the stock. However, investors should note that the stock already trades at a substantial premium to the analyst's attractive entry of $360, and buybacks at these levels may not create long-term value. The core risks—China accounting for 34-37% of revenue with potential export license constraints—remain unaddressed and could lead to a sharp revenue decline. The buyback program may support EPS in the near term but could also mask underlying operational challenges if China restrictions tighten. Therefore, investors should not rush in based on the buyback alone; instead, monitor the upcoming quarterly results and China revenue mix for confirmation of the thesis.

Thesis delta

The buyback authorization is a positive capital allocation development that could support the stock price and per-share metrics, but it does not change the fundamental WAIT thesis. The key risks of high valuation and China exposure remain, and the buyback may even suggest management is willing to support the stock despite these risks. The thesis remains unchanged pending further evidence on China stability and valuation correction.